KJ Pyr 9 (KJ-Pyr-9) acts by disrupting the MYC-MAX complex formation within cells, as observed in protein fragment complementation assays[1]. KJ Pyr 9 specifically targets and inhibits MYC-induced oncogenic transformation in cell cultures, showing minimal or negligible impact on the oncogenic functions of various unrelated oncoproteins[1]. KJ Pyr 9 notably affects the proliferation of cells overexpressing MYC, both human and avian, and distinctively reduces the transcriptional signature driven by MYC[1]. KJ Pyr 9 efficacy has been tested against three cell lines known for their dependence on enhanced MYC activity: NCI-H460, MDA-MB-231, and SUM-159PT, successfully inhibiting their proliferation with IC50 values ranging between 5 and 10 μM[1]. Burkitt lymphoma cell lines, characterized by constitutively high c-MYC expression, show even greater sensitivity to KJ Pyr 9, with IC50 values between 1 and 2.5 μM[1].
体内研究
Additionally, KJ Pyr 9 administered intraperitoneally at 10 mg/kg daily for 31 days has been found capable of arresting tumor growth[1].
体外研究
KJ Pyr 9 (KJ-Pyr-9) acts by disrupting the MYC-MAX complex formation within cells, as observed in protein fragment complementation assays[1].
KJ Pyr 9 specifically targets and inhibits MYC-induced oncogenic transformation in cell cultures, showing minimal or negligible impact on the oncogenic functions of various unrelated oncoproteins[1].
KJ Pyr 9 notably affects the proliferation of cells overexpressing MYC, both human and avian, and distinctively reduces the transcriptional signature driven by MYC[1].
KJ Pyr 9 efficacy has been tested against three cell lines known for their dependence on enhanced MYC activity: NCI-H460, MDA-MB-231, and SUM-159PT, successfully inhibiting their proliferation with IC50 values ranging between 5 and 10 μM[1].
Burkitt lymphoma cell lines, characterized by constitutively high c-MYC expression, show even greater sensitivity to KJ Pyr 9, with IC50 values between 1 and 2.5 μM[1].
搜索
